Sai Life Sciences has reported a strong financial performance for the second quarter of FY27, with revenue from operations rising 23% year-on-year to Rs. 659 crore, compared with Rs. 537 crore in the corresponding quarter last year.

 

The Hyderabad-based contract research, development and manufacturing organisation (CRDMO) also reported a 20% increase in EBITDA to Rs. 187 crore, while EBITDA margin stood at a healthy 28%, against 29% in Q2 FY26. Profit after tax (PAT) grew 17% to Rs. 98 crore from Rs. 84 crore a year ago.

 

For the first half of FY27, revenue climbed 17% to Rs. 1,213 crore, compared with Rs. 1,034 crore in H1 FY26. EBITDA increased 19% to Rs. 335 crore, while PAT rose 19% to Rs. 172 crore.

 

The company attributed its performance to sustained business momentum, growing traction with global pharmaceutical companies and increasing adoption of its integrated outsourcing model.

 

Commenting on the performance, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “Q2 FY27 was a strong quarter for Sai, with continued business momentum and progress across our key strategic priorities. 

 

"We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabilities required to support customers over the long term. Importantly, we are seeing customer engagements evolve from individual projects into larger, more strategic relationships spanning discovery, development and manufacturing."

 

CFO Siva Chittor said the company's growth was broad-based, with both its contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) businesses delivering healthy growth.

 

“We are pleased to report a healthy performance this quarter, with revenue growing by 23% year-on-year. The performance was broad-based, with both CRO and CDMO delivering healthy growth, while EBITDA margins stood at 28%. We continue to expect a stronger second half, supported by the progression of our development and commercial pipeline and the ramp-up of new capacity. Our capacity and capability expansion programme remains on track with a total of Rs. 621 crore invested in H1 FY27.”

 

The company expects a stronger second half, driven by the progression of its development and commercial pipeline and the ramp-up of new capacity.

 

With customer relationships expanding beyond individual projects into integrated discovery, development and manufacturing engagements, Sai Life Sciences is looking to strengthen its position in the global CRDMO market.